BioCryst Pharmaceuticals (BCRX) Institutional Ownership

85.88% of BioCryst Pharmaceuticals' stock is owned by institutional investors. Learn more on BCRX's institutional investor holdings.

Of the 268 institutional investors that purchased BioCryst Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($15.83M), Janus Henderson Group PLC ($8.81M), Deerfield Management Company L.P. ($7.48M), Perceptive Advisors LLC ($7.43M), Arrowstreet Capital Limited Partnership ($5.03M), Bank of America Corp DE ($4.96M), and Assenagon Asset Management S.A. ($3.61M).

Institutional investors have bought a total of 108,384,462 shares in the last 24 months. This purchase volume represents approximately $903.79M in transactions.

Of the 110 institutional investors that sold BioCryst Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Assenagon Asset Management S.A. ($3.39M), Avoro Capital Advisors LLC ($3.25M), Voloridge Investment Management LLC ($2.02M), Millennium Management LLC ($1.87M), Alkeon Capital Management LLC ($1.75M), Ameriprise Financial Inc. ($1.64M), and Renaissance Technologies LLC ($1.36M).

Institutional investors have sold a total of 33,199,018 shares in the last 24 months. This volume of shares sold represents approximately $270.03M in transactions.